Strategic-Technological Analysis: MyoSwiss AG

The MyoSwiss AG story begins in 2017, when two Swiss researchers at ETH Zurich’s Sensory-Motor Systems Lab applied robotics and textile innovation to human mobility. Their flagship Myosuit is a lightweight, garment-style exoskeleton that adds a wearable layer of robotic muscle to a user’s legs.

As a medical device now CE-certified and marketed in Europe , it has drawn notice beyond the rehabilitation community. But MyoSwiss’s technology – soft, sensory-controlled actuation that eases leg load – also intersects with emerging defense concerns. European planners eye advanced human-extension systems as one element of future dismounted capability.

This analysis answers: What does MyoSwiss's Myosuit garment-style exoskeleton do to add a wearable layer of robotic muscle through soft, sensory-controlled actuation? How mature is the Myosuit as a CE-certified medical device, and how does it intersect with emerging European dismounted-capability concerns? How does MyoSwiss's origin at ETH Zurich's Sensory-Motor Systems Lab shape its partnerships and market beyond rehabilitation? What capability gaps and dependencies affect MyoSwiss's dual-use path toward human-extension defence applications?